ABSTRACT
Iron is essential for cellular functions, but in excessive amounts it is toxic to cells. The harmful effects are related to increased oxidative stress and production of reactive oxygen species causing oxidative damage to lipids, proteins, and nucleic acids. Heavy iron overload as occurs in primary and secondary hemochromatosis can cause fibrosis of various parenchymal organs such as the liver, heart, and pancreas. Lesser degrees of hepatic iron deposition are also associated with, and seem to be risk factors for, certain nonhemochromatotic liver diseases. Porphyria cutanea tarda is associated with hepatic iron overload and responds to iron-reduction therapy. Other recent evidence indicates that the prevalence of HFE gene mutations is increased in chronic viral hepatitis and that patients with chronic hepatitis C harboring especially the C282Y mutation are more likely to suffer from advanced hepatic fibrosis or cirrhosis and to do so at younger ages. In this article we review selected nonhemochromatotic disorders in which iron can play an important comorbid role.
KEYWORDS
Alcohol - cirrhosis - hepatitis C - iron - nonalcoholic fatty liver disease - nonalcoholic steatohepatitis - porphyria cutanea tarda
REFERENCES
1
Ioannou G N, Dominitz J A, Weiss N S, Heagerty P J, Kowdley K V.
The effect of alcohol consumption on the prevalence of iron overload, iron deficiency, and iron deficiency anemia.
Gastroenterology.
2004;
126
1293-1301
2
Bonkovsky H L, Obando J V.
Role of HFE gene mutations in liver diseases other than hereditary hemochromatosis.
Curr Gastroenterol Rep.
1999;
1
30-37
3
Milman N, Graudal N, Hegnhoj J, Christoffersen P, Pedersen N S.
Relationships among serum iron status markers, chemical and histochemical liver iron content in 117 patients with alcoholic and non-alcoholic hepatic disease.
Hepatogastroenterology.
1994;
41
20-24
4
De Feo T M, Fargion S, Duca L et al..
Non-transferrin-bound iron in alcohol abusers.
Alcohol Clin Exp Res.
2001;
25
1494-1499
5
Suzuki Y, Saito H, Suzuki M et al..
Up-regulation of transferrin receptor expression in hepatocytes by habitual alcohol drinking is implicated in hepatic iron overload in alcoholic liver disease.
Alcohol Clin Exp Res.
2002;
26(8 Suppl)
26S-31S
6
Pascoe A, Kerlin P, Steadman C et al..
Spur cell anaemia and hepatic iron stores in patients with alcoholic liver disease undergoing orthotopic liver transplantation.
Gut.
1999;
45
301-305
7
Pascoe A, Kerlin P, Jones D.
Spur cell anemia explains the iron overload in advanced cirrhosis (C282Y negative).
Hepatology.
2000;
32
159
8
Mazzanti R, Srai K S, Debnam E S, Boss A M, Gentilini P.
The effect of chronic ethanol consumption on iron absorption in rats.
Alcohol Alcohol.
1987;
22
47-52
9
Duane P, Raja K B, Simpson R J, Peters T J.
Intestinal iron absorption in chronic alcoholics.
Alcohol Alcohol.
1992;
27
539-544
10
Bonkovsky H L, Lambrecht R W, Shan Y.
Iron as a co-morbid factor in nonhemochromatotic liver disease.
Alcohol.
2003;
30
137-144
11 Harrison-Findik D, Schafer D, Klein E, Gollan J. Hepatic hepcidin expression is regulated by ethanol and acetaldehyde: role of IL-6 and oxidative stress. BioIron 2005: Prague, Czech Republic 2005: 24
12
Nemeth E, Tuttle M S, Powelson J et al..
Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization.
Science.
2004;
306
2090-2093
13
Pietrangelo A.
Hereditary hemochromatosis-a new look at an old disease.
N Engl J Med.
2004;
350
2383-2397
14
Sabesin S M, Thomas L B.
Parenchymal siderosis in patients with preexisting portal cirrhosis. A pathologic entity simulating idiopathic and transfusional hemochromatosis.
Gastroenterology.
1964;
46
477-485
15
Powell L W.
Normal human iron storage and its relation to ethanol consumption.
Australas Ann Med.
1966;
15
110-115
16
Lundvall O, Weinfeld A, Lundin P.
Iron stores in alcohol abusers. I. Liver iron.
Acta Med Scand.
1969;
185
259-269
17
Jakobovits A W, Morgan M Y, Sherlock S.
Hepatic siderosis in alcoholics.
Dig Dis Sci.
1979;
24
305-310
18
MacDonald R A.
Primary hemochromatosis: inherited or acquired?.
Prog Hematol.
1966;
5
324-353
19
Regoeczi E, Chindemi P A, Debanne M T.
Transferrin glycans: a possible link between alcoholism and hepatic siderosis.
Alcohol Clin Exp Res.
1984;
8
287-292
20
Beguin Y, Bergamaschi G, Huebers H A, Finch C A.
The behavior of asialotransferrin-iron in the rat.
Am J Hematol.
1988;
29
204-210
21
Rouach H, Houze P, Gentil M, Orfanelli M T, Nordmann R.
Effects of acute ethanol administration on the uptake of 59Fe-labeled transferrin by rat liver and cerebellum.
Biochem Pharmacol.
1994;
47
1835-1841
22
Chapman R W, Morgan M Y, Boss A M, Sherlock S.
Acute and chronic effects of alcohol on iron absorption.
Dig Dis Sci.
1983;
28
321-327
23
Tsukamoto H, Horne W, Kamimura S et al..
Experimental liver cirrhosis induced by alcohol and iron.
J Clin Invest.
1995;
96
620-630
24
Adams P C, Agnew S.
Alcoholism in hereditary hemochromatosis revisited: prevalence and clinical consequences among homozygous siblings.
Hepatology.
1996;
23
724-727
25
Loreal O, Deugnier Y, Moirand R et al..
Liver fibrosis in genetic hemochromatosis. Respective roles of iron and non-iron-related factors in 127 homozygous patients.
J Hepatol.
1992;
16(1-2)
122-127
26
Fargion S, Mandelli C, Piperno A et al..
Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis.
Hepatology.
1992;
15
655-659
27
Fargion S, Fracanzani A L, Piperno A et al..
Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis.
Hepatology.
1994;
20
1426-1431
28
Fletcher L M, Powell L W.
Hemochromatosis and alcoholic liver disease.
Alcohol.
2003;
30
131-136
29
Grove J, Daly A K, Burt A D et al..
Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease.
Gut.
1998;
43
262-266
30
Thursz M, Mantafounis D, Yallo R.
Severe alcoholic liver disease is associated with the haemochromatosis gene mutant.
Gastroenterology.
1997;
112
A1401
31
Frenzer A, Rudzki Z, Norton I D, Butler W J, Roberts-Thomson I C.
Heterozygosity of the haemochromatosis mutation, C282Y, does not influence susceptibility to alcoholic cirrhosis.
Scand J Gastroenterol.
1998;
33
1324
32
Raynard B, Balian A, Fallik D et al..
Risk factors of fibrosis in alcohol-induced liver disease.
Hepatology.
2002;
35
635-638
33
Bonkovsky H L, Banner B F, Lambrecht R W, Rubin R B.
Iron in liver diseases other than hemochromatosis.
Semin Liver Dis.
1996;
16
65-82
34
Bonkovsky H L, Poh-Fitzpatrick M, Pimstone N et al..
Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America.
Hepatology.
1998;
27
1661-1669
35
Bonkovsky H L, Lambrecht R W.
Iron-induced liver injury.
Clin Liver Dis.
2000;
4
409-429
vi-viii
36
Lambrecht R W, Bonkovsky H L.
Hemochromatosis and porphyria.
Semin Gastrointest Dis.
2002;
13
109-119
37
Elder G H, Sheppard D M, De Salamanca R E, Olmos A.
Identification of two types of porphyria cutanea tarda by measurement of erythrocyte uroporphyrinogen decarboxylase.
Clin Sci (Lond).
1980;
58
477-484
38
Koszo F, Morvay M, Dobozy A, Simon N.
Erythrocyte uroporphyrinogen decarboxylase activity in 80 unrelated patients with porphyria cutanea tarda.
Br J Dermatol.
1992;
126
446-449
39
Elder G H, Urquhart A J, De Salamanca R E, Munoz J J, Bonkovsky H L.
Immunoreactive uroporphyrinogen decarboxylase in the liver in porphyria cutanea tarda.
Lancet.
1985;
2
229-233
40
Gorman N, Ross K L, Walton H S et al..
Uroporphyria in mice: thresholds for hepatic CYP1A2 and iron.
Hepatology.
2002;
35
912-921
41
Sinclair P R, Gorman N, Walton H S et al..
CYP1A2 is essential in murine uroporphyria caused by hexachlorobenzene and iron.
Toxicol Appl Pharmacol.
2000;
162
60-67
42
Sinclair P R, Gorman N, Dalton T et al..
Uroporphyria produced in mice by iron and 5-aminolaevulinic acid does not occur in Cyp1a2(-/-) null mutant mice.
Biochem J.
1998;
330(Pt 1)
149-153
43
Smith A G, Clothier B, Carthew P et al..
Protection of the Cyp1a2(-/-) null mouse against uroporphyria and hepatic injury following exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin.
Toxicol Appl Pharmacol.
2001;
173
89-98
44
Sinclair P R, Gorman N, Trask H W et al..
Uroporphyria caused by ethanol in Hfe(-/-) mice as a model for porphyria cutanea tarda.
Hepatology.
2003;
37
351-358
45
Roberts A G, Whatley S D, Morgan R R, Worwood M, Elder G H.
Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda.
Lancet.
1997;
349
321-323
46
Bulaj Z J, Phillips J D, Ajioka R S et al..
Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda.
Blood.
2000;
95
1565-1571
47
Egger N G, Goeger D E, Payne D A, Miskovsky E P, Weinman S A, Anderson K E.
Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency.
Dig Dis Sci.
2002;
47
419-426
48
Tannapfel A, Stolzel U, Kostler E et al..
C282Y and H63D mutation of the hemochromatosis gene in German porphyria cutanea tarda patients.
Virchows Arch.
2001;
439
1-5
49
Stuart K A, Busfield F, Jazwinska E C et al..
The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients.
J Hepatol.
1998;
28
404-409
50
Sampietro M, Piperno A, Lupica L et al..
High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda.
Hepatology.
1998;
27
181-184
51
Clark J M, Brancati F L, Diehl A M.
The prevalence and etiology of elevated aminotransferase levels in the United States.
Am J Gastroenterol.
2003;
98
960-967
52
Clark J M, Brancati F L, Diehl A M.
Nonalcoholic fatty liver disease.
Gastroenterology.
2002;
122
1649-1657
53
Ludwig J, Viggiano T R, McGill D B, Oh B J.
Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.
Mayo Clin Proc.
1980;
55
434-438
54
Day C P, James O F.
Steatohepatitis: a tale of two “hits”?.
Gastroenterology.
1998;
114
842-845
55
Loguercio C, De S T, D'Auria M V et al..
Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver.
Dig Liver Dis.
2004;
36
398-405
56
Marchesini G, Brizi M, Morselli-Labate A M et al..
Association of nonalcoholic fatty liver disease with insulin resistance.
Am J Med.
1999;
107
450-455
57
Marchesini G, Brizi M, Bianchi G et al..
Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.
Diabetes.
2001;
50
1844-1850
58
Knobler H, Schattner A, Zhornicki T et al..
Fatty liver-an additional and treatable feature of the insulin resistance syndrome.
QJM.
1999;
92
73-79
59
Cortez-Pinto H, Camilo M E, Baptista A, De Oliveira A G, De Moura M C.
Non-alcoholic fatty liver: another feature of the metabolic syndrome?.
Clin Nutr.
1999;
18
353-358
60
Tankurt E, Biberoglu S, Ellidokuz E et al..
Hyperinsulinemia and insulin resistance in non-alcoholic steatohepatitis.
J Hepatol.
1999;
31
963
61
Sanyal A J, Campbell-Sargent C, Mirshahi F et al..
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.
Gastroenterology.
2001;
120
1183-1192
62
Willner I R, Waters B, Patil S R, Reuben A, Morelli J, Riely C A.
Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease.
Am J Gastroenterol.
2001;
96
2957-2961
63
Loguercio C, De Girolamo V, de Sio I et al..
Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects.
J Hepatol.
2001;
35
568-574
64
Chitturi S, Abeygunasekera S, Farrell G C et al..
NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome.
Hepatology.
2002;
35
373-379
65
Pagano G, Pacini G, Musso G et al..
Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association.
Hepatology.
2002;
35
367-372
66
Comert B, Mas M R, Erdem H et al..
Insulin resistance in non-alcoholic steatohepatitis.
Dig Liver Dis.
2001;
33
353-358
67
Bacon B R, Farahvash M J, Janney C G, Neuschwander-Tetri B A.
Nonalcoholic steatohepatitis: an expanded clinical entity.
Gastroenterology.
1994;
107
1103-1109
68
George D K, Goldwurm S, MacDonald G A et al..
Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis.
Gastroenterology.
1998;
114
311-318
69
Bonkovsky H L, Jawaid Q, Tortorelli K et al..
Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis.
J Hepatol.
1999;
31
421-429
70
Angulo P, Keach J C, Batts K P, Lindor K D.
Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.
Hepatology.
1999;
30
1356-1362
71
Younossi Z M, Gramlich T, Bacon B R et al..
Hepatic iron and nonalcoholic fatty liver disease.
Hepatology.
1999;
30
847-850
72
Facchini F S, Hua N W, Stoohs R A.
Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease.
Gastroenterology.
2002;
122
931-939
73
Desai T, Chiorean M.
Phlebotomy reduces transaminase levels in patients with chronic non-alcoholic steatohepatitis.
Gastroenterology.
1998;
114
A1233
74
Nitecki J, Jackson F, Allen M.
Effect of phlebotomy on non-alcoholic steatohepatitis (NASH).
Gastroenterology.
2000;
118
A1474
75
Valenti L, Fracanzani A L, Fargion S.
Effect of iron depletion in patients with nonalcoholic fatty liver disease without carbohydrate intolerance.
Gastroenterology.
2003;
124
866-867
76
Fernandez-Real J M, Lopez-Bermejo A, Ricart W.
Iron stores, blood donation, and insulin sensitivity and secretion.
Clin Chem.
2005;
51
1201-1205
77
[No authors listed.] .
Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium.
J Viral Hepat.
1999;
6
35-47
78
Alter M J.
Hepatitis C virus infection in the United States.
J Hepatol.
1999;
31(Suppl 1)
88-91
79
Tong M J, el-Farra N S, Reikes A R, Co R L.
Clinical outcomes after transfusion-associated hepatitis C.
N Engl J Med.
1995;
332
1463-1466
80
Seeff L B.
The natural history of chronic hepatitis C virus infection.
Clin Liver Dis.
1997;
1
587-602
81
Blumberg B S, Lustbader E D, Whitford P L.
Changes in serum iron levels due to infection with hepatitis B virus.
Proc Natl Acad Sci USA.
1981;
78
3222-3224
82
Di Bisceglie A M, Axiotis C A, Hoofnagle J H, Bacon B R.
Measurements of iron status in patients with chronic hepatitis.
Gastroenterology.
1992;
102
2108-2113
83
Arber N, Konikoff F M, Moshkowitz M et al..
Increased serum iron and iron saturation without liver iron accumulation distinguish chronic hepatitis C from other chronic liver diseases.
Dig Dis Sci.
1994;
39
2656-2659
84
Bonkovsky H L, Banner B F, Rothman A L.
Iron and chronic viral hepatitis.
Hepatology.
1997;
25
759-768
85
Shan Y, Lambrecht R W, Bonkovsky H L.
Association of hepatitis C virus infection with serum iron status: analysis of data from the third National Health and Nutrition Examination Survey.
Clin Infect Dis.
2005;
40
834-841
86
Sartori M, Andorno S, La T G et al..
Evaluation of iron status in patients with chronic hepatitis C.
Ital J Gastroenterol Hepatol.
1998;
30
396-401
87
Barton A L, Banner B F, Cable E E, Bonkovsky H L.
Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy.
Am J Clin Pathol.
1995;
103
419-424
88
Ikura Y, Morimoto H, Johmura H, Fukui M, Sakurai M.
Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C.
Am J Gastroenterol.
1996;
91
1367-1373
89
Van Thiel D H, Friedlander L, Fagiuoli S, Wright H I, Irish W, Gavaler J S.
Response to interferon alpha therapy is influenced by the iron content of the liver.
J Hepatol.
1994;
20
410-415
90
Olynyk J K, Reddy K R, Di Bisceglie A M et al..
Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C.
Gastroenterology.
1995;
108
1104-1109
91
Piperno A, Sampietro M, D'Alba R et al..
Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C.
Liver.
1996;
16
248-254
92
Fargion S, Fracanzani A L, Sampietro M et al..
Liver iron influences the response to interferon alpha therapy in chronic hepatitis C.
Eur J Gastroenterol Hepatol.
1997;
9
497-503
93
Fong T L, Han S H, Tsai N C et al..
A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C.
J Hepatol.
1998;
28
369-374
94
Fontana R J, Israel J, LeClair P et al..
Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial.
Hepatology.
2000;
31
730-736
95
Fargion S, Fracanzani A L, Rossini A et al..
Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study.
Am J Gastroenterol.
2002;
97
1204-1210
96
Di Bisceglie A M, Bonkovsky H L, Chopra S et al..
Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial.
Hepatology.
2000;
32
135-138
97
Tsai N C, Zuckerman E, Han S H, Goad K, Redeker A G, Fong T L.
Effect of iron depletion on long-term response to interferon-alpha in patients with chronic hepatitis C who previously did not respond to interferon therapy.
Am J Gastroenterol.
1997;
92
1831-1834
98
Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N.
Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron.
Am J Gastroenterol.
1994;
89
986-988
99
Sartori M, Andorno S, Rigamonti C, Grossini E, Nicosia G, Boldorini R.
Chronic hepatitis C is mild in menstruating women.
J Gastroenterol Hepatol.
2000;
15
1411-1417
100
Yano M, Hayashi H, Wakusawa S et al..
Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C.
Am J Gastroenterol.
2002;
97
133-137
101
Kimura F, Hayashi H, Yano M et al..
Additional effect of low iron diet on iron reduction therapy by phlebotomy for chronic hepatitis C.
Hepatogastroenterology.
2005;
52
563-566
102
Fried M W, Shiffman M L, Reddy K R et al..
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
N Engl J Med.
2002;
347
975-982
103
Manns M P, McHutchison J G, Gordon S C et al..
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Lancet.
2001;
358
958-965
104
Bonkovsky H L.
Iron as a comorbid factor in chronic viral hepatitis.
Am J Gastroenterol.
2002;
97
1-4
105
Boucher E, Bourienne A, Adams P, Turlin B, Brissot P, Deugnier Y.
Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment.
Gut.
1997;
41
115-120
106
Piperno A, Vergani A, Malosio I et al..
Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations.
Hepatology.
1998;
28
1105-1109
107
Smith B C, Gorve J, Guzail M A et al..
Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C.
Hepatology.
1998;
27
1695-1699
108
Kazemi-Shirazi L, Datz C, Maier-Dobersberger T et al..
The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C.
Gastroenterology.
1999;
116
127-134
109
Martinelli A L, Franco R F, Villanova M G et al..
Are haemochromatosis mutations related to the severity of liver disease in hepatitis C virus infection?.
Acta Haematol.
2000;
102
152-156
110
Tung B Y, Emond M J, Bronner M P, Raaka S D, Cotler S J, Kowdley K V.
Hepatitis C iron status, and disease severity: relationship with HFE mutations.
Gastroenterology.
2003;
124
318-326
111
Bonkovsky H L, Troy N, McNeal K et al..
Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C.
J Hepatol.
2002;
37
848-854
112
de Sousa M, Porto G.
The immunological system in hemochromatosis.
J Hepatol.
1998;
28(Suppl 1)
1-7
113
Pietrangelo A.
Hemochromatosis gene modifies course of hepatitis C viral infection.
Gastroenterology.
2003;
124
1509-1523
114
Lustbader E D, Hann H W, Blumberg B S.
Serum ferritin as a predictor of host response to hepatitis B virus infection.
Science.
1983;
220
423-425
115
Park C H, Valore E V, Waring A J, Ganz T.
Hepcidin, a urinary antimicrobial peptide synthesized in the liver.
J Biol Chem.
2001;
276
7806-7810
116
Knutson M D, Oukka M, Koss L M, Aydemir F, Wessling-Resnick M.
Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin.
Proc Natl Acad Sci USA.
2005;
102
1324-1328
117
Roetto A, Papanikolaou G, Politou M et al..
Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis.
Nat Genet.
2003;
33
21-22
118
Detivaud L, Nemeth E, Boudjema K et al..
Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function.
Blood.
2005;
106
746-748
119 Ohtake T, Inoue M, Miyoshi S, Suzuki Y, Saito H, Kohgo Y. Hepcidin is decreased in alcohol abuse. BioIron 2005: Prague, Czech Republic. 2005: 73
120
Aoki C A, Rossaro L, Ramsamooj R, Brandhagen D, Burritt M F, Bowlus C L.
Liver hepcidin mRNA correlates with iron stores, but not inflammation, in patients with chronic hepatitis C.
J Clin Gastroenterol.
2005;
39
71-74
Herbert L BonkovskyM.D.
MC-1111, University of Connecticut Health Center
263 Farmington Ave., Farmington, CT 06030
Email: bonkovsky@uchc.edu